Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Discovery
Ligand to acquire protein technology firm Pfenex
by Ryan Cross
August 14, 2020
| A version of this story appeared in
Volume 98, Issue 31
Ligand Pharmaceuticals is paying more than a 50% premium to acquire all outstanding shares of Pfenex for $438 million. Ligand earns royalties and licensing fees from drug companies that use its antibody and small-molecule discovery platforms, and from its drug solubilization business. Pfenex licenses a recombinant protein production method that it says is suited for making complex proteins at large scale. Its owners could earn an extra $78 million if they meet an undisclosed milestone by the end of 2021.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X